

# SARS-CoV-2 testing

# The BD Kit for Rapid Detection of SARS-CoV-2 at the point of care

The easy-to-use testing kit that provides SARS-CoV-2 results in 15 minutes




## Get ready for SARS-CoV-2 testing

When your patients are in need of reliable and rapid SARS-CoV-2 testing, turn to the BD Kit for Rapid Detection of SARS-CoV-2. Offering an easy-to-use point of care test, with results in 15 minutes.

### One result<sup>1</sup>

- Assay results designed to be read visually
- Indicated for use in both asymptomatic and symptomatic individuals, who are suspected of SARS-CoV-2 infection by their healthcare provider
- Results in just 15 minutes
- Easily performed and interpreted by Healthcare professionals or trained users
- Detection of SARS-CoV-2 antigen (nucleocapsid protein), in nasal swabs
- Reliable results, 91% PPA\* compared to reference PCR method
- Provides intuitive sample processing with prefilled, single-use reaction tubes

#### Time to results:



- 1. BD Kit For Rapid Detection of SARS-CoV-2 [package insert]. Franklin Lakes, NJ: Becton, Dickinson and Company; 2021
- Clinical performance data taken from Study 1 in the package insert. Performance established with patients reporting two or more self-reported symptoms.

BD - Europe, Terre Bonne Park – A4, Route de Crassier 17, 1262 Eysins, Switzerland

#### bd.com

Unless otherwise indicated, all products are CE-marked in compliance with the European In Vitro Diagnostic Medical Devices Directive 98/79/EC.

BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2021 BD. All rights reserved. BD-29754

### **Clinical performance<sup>1</sup>**

Positive Percent	Negative Percent
Agreement (PPA)	Agreement (NPA)
91.1%*	99.6%*
(95% Confidence Interval	(95% Confidence Interval
(C.I.), 80.7%-96.1%)	(C.I.), 97.9%-99.9%)
Positive Predictive	Negative Predictive
Value (PPV)	Value (NPV)
	3

Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.



Ordering information	Cat. no.	Qty.
BD Kit for Rapid Detection of SARS-CoV-2	256091	30 tests

